T2 Biosystems Inc
TTOO
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.22K
Close$
$3.41
170260% upside
Current Fair Value
170260% upsideUndervalued by 170260% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11,218.00 |
|---|---|
| Enterprise Value | $17.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-19.19 |
| Beta | 8.26 |
| Outstanding Shares | 17,892,606 |
Return
| Return on Equity | 369.21% |
|---|---|
| Return on Assets | -239.10% |
| Return on Invested Capital | 656.68% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 2.23 |
| Enterprise Value to EBIT | -0.41 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.12 |
| Debt to Equity | -1.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▲ 0.00% |
|---|---|
| Total Invested | $1▼ 80.00% |
| Investors Holding | 10% |
ESG Score
No data
About T2 Biosystems Inc
CEO: John Sperzel